Macrophage News and Research

RSS

A macrophage is a type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells.

Researchers identify novel viral sensor complex

Double-stranded (ds) RNA viruses are a diverse group of viruses that include rotaviruses, a common cause of gastroenteritis. The ability of the immune system to detect and destroy viruses is critical for human health and survival.

24 Jun 2011

Scientists uncover how immune system responds to invading anthrax bacteria

Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.

17 Jun 2011

Researchers discover genetic factor that can regulate obesity-induced inflammation

Researchers at Case Western Reserve University School of Medicine have discovered a genetic factor that can regulate obesity-induced inflammation that contributes to chronic health problems.

14 Jun 2011

Researchers identify key molecule responsible for breast tumor metastasis

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified a key player in the spread of breast cancer. The findings, published today in the online edition of Nature, identify a critical molecule that helps cancer spread beyond the primary tumor.

9 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Mimicry allows bacteria to evade host's defense responses

Deadly bacteria may be evolving antibiotic resistance by mimicking human proteins, according to a new study by the Translational Genomics Research Institute (TGen).

3 Jun 2011

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor, can also suppress aspects of inflammation.

23 May 2011

Blood stored in banks may undergo changes and damage

New research provides evidence for significant differences between new and old red blood cells used for transfusions and could provide a cheap, rapid and effective way to monitor the quality of blood supplies.

21 May 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

Pediatric researchers find potential tools for controlling cytokine storm

By analyzing complex interactions of the immune system in an animal study, pediatric researchers have found potential tools for controlling a life-threatening condition called a cytokine storm that may strike children who have juvenile arthritis and other autoimmune diseases.

17 May 2011

Gene manipulation can improve survival rates during sepsis infection

Sepsis is a major killer in hospital intensive care units. Researchers at Case Western Reserve University School of Medicine have found that manipulating a genetic factor that can launch or throttle the body's defenses can improve survival rates during bacterial infection.

13 May 2011

Cancers use body's own defences to resist drugs

CANCER RESEARCH UK scientists have discovered that tumours are able to recruit part of the body's defence system to protect them from the effect of a drug designed to block the supply of blood to the tumour.

4 May 2011

GM-CSF appears to be key culprit in multiple sclerosis onset

Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

GM-SCF therapy can reduce flu symptoms and prevent death

New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor significantly reduces flu symptoms and prevents death after a lethal dose influenza virus.

22 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

The U.S. Food and Drug Administration today approved Actemra, given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis in children ages 2 years and older.

15 Apr 2011